AV-COVID-19

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameAV-COVID-19

Drug Alias NameDC-ATADendritic cell vaccine AV-COVID-19

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndonesia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAivita Biomedical Inc

China Registration ClassN/A

Develop Information

Active CompaniesAivita Biomedical Inc

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A